marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-23-2024
Viking Therapeutics Balance Sheet 2011-2024 | VKTX
Annual Balance Sheet Viking Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-54.3 M | -35.1 M | - | -28.8 M | -7.72 M | -24.8 M | -5.54 M | 194 K | 14.7 M | 813 K | 99.1 K | 42.8 K | - |
Long Term Debt |
936 K | 1.26 M | - | - | - | - | - | - | 2.15 M | 1.26 M | 232 K | 42.8 K | - |
Long Term Debt Current |
324 K | 304 K | 29 K | 330 K | 302 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
936 K | 1.26 M | - | - | 360 K | 12 K | - | 16.3 K | 4.74 M | 2.65 M | 304 K | 51 K | - |
Total Current Liabilities |
19.1 M | 21.9 M | 8.78 M | 12.1 M | 6.78 M | 4.55 M | 8.66 M | 6.48 M | 1.98 M | - | - | - | - |
Total Liabilities |
20.1 M | 23.2 M | 8.78 M | 29 K | 7.14 M | 4.56 M | 8.66 M | 6.49 M | 6.71 M | 25.2 M | 431 K | 105 K | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-378 M | -292 M | -223 M | - | -129 M | -103 M | -80.9 M | -60.3 M | -45.5 M | -22.1 M | -257 K | -111 K | - |
Total Assets |
368 M | 169 M | 211 M | 257 M | 284 M | 302 M | 22.1 M | 14.5 M | 15.4 M | 3.04 M | 180 K | - | - |
Cash and Cash Equivalents |
55.5 M | 36.6 M | 26.4 M | 29.1 M | 8.38 M | 24.8 M | 8.99 M | 3.08 M | 769 K | 756 K | - | - | - |
Book Value |
348 M | 145 M | 202 M | 256 M | 277 M | 298 M | 13.5 M | 8.04 M | 8.72 M | -22.1 M | -251 K | -105 K | - |
Total Shareholders Equity |
348 M | 145 M | 202 M | 244 M | 277 M | 298 M | 13.5 M | 8.04 M | 8.72 M | -22.1 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Viking Therapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
755 K | 766 K | 936 K | 1.02 M | 1.1 M | 1.18 M | 1.26 M | 1.34 M | - | 1.49 M | - | - | - | - | 29 K | 29 K | 29 K | 29 K | 360 K | 360 K | 360 K | 360 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
755 K | 766 K | 936 K | 1.02 M | 1.1 M | 1.18 M | 1.26 M | 1.34 M | - | 1.49 M | - | - | - | - | 29 K | 29 K | 29 K | 29 K | 360 K | 360 K | 360 K | 360 K | 12 K | 12 K | 12 K | 12 K | - | - | 6.05 K | 4.22 M | 16.3 K | 16.3 K | 16.3 K | 16.3 K | 4.74 M | 4.74 M | 4.74 M | 4.74 M | 2.65 M | 2.65 M | 2.65 M | 2.65 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
26.4 M | 25.9 M | 20.1 M | 14.4 M | 14.6 M | 16.8 M | 23.2 M | 15.4 M | - | 12.8 M | 8.78 M | 11.4 M | 12.9 M | 12.9 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 7.14 M | 7.14 M | 7.14 M | 7.14 M | 4.56 M | 4.56 M | 4.56 M | 4.56 M | 8.66 M | 8.66 M | 8.66 M | 8.66 M | 6.49 M | 6.49 M | 6.49 M | 6.49 M | 6.71 M | 6.71 M | 6.71 M | 6.71 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-452 M | -428 M | -378 M | -353 M | -331 M | -312 M | -292 M | -272 M | - | -239 M | -223 M | -211 M | -198 M | -182 M | -168 M | -168 M | -168 M | -168 M | -129 M | -129 M | -129 M | -129 M | -103 M | -103 M | -103 M | -103 M | -80.9 M | -80.9 M | -80.9 M | -80.9 M | -60.3 M | -60.3 M | -60.3 M | -60.3 M | -45.5 M | -45.5 M | -45.5 M | -45.5 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
938 M | 947 M | 368 M | 383 M | 401 M | 151 M | 169 M | 167 M | - | 195 M | 211 M | 224 M | 238 M | 250 M | 257 M | 257 M | 257 M | 257 M | 284 M | 284 M | 284 M | 284 M | 302 M | 302 M | 302 M | 302 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 3.04 M | 3.04 M | 3.04 M | 3.04 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
50.3 M | 43.9 M | 55.5 M | 37.2 M | 69.5 M | 18.4 M | 36.6 M | 29.4 M | - | 12.5 M | 26.4 M | 11.3 M | 8.83 M | 16.8 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 8.38 M | 8.38 M | 8.38 M | 8.38 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 769 K | 769 K | 769 K | 769 K | 756 K | 756 K | 756 K | 756 K | 180 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
911 M | 921 M | 348 M | 368 M | 386 M | 134 M | 145 M | 151 M | - | 182 M | 202 M | 213 M | 225 M | 237 M | 244 M | 244 M | 244 M | 244 M | 277 M | 277 M | 277 M | 277 M | 298 M | 298 M | 298 M | 298 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 8.72 M | 8.72 M | 8.72 M | 8.72 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
911 M | 921 M | 348 M | 368 M | 386 M | 134 M | 145 M | 151 M | 165 M | 182 M | 202 M | 213 M | 225 M | 237 M | 244 M | 244 M | 244 M | 244 M | 277 M | 277 M | 277 M | 277 M | 298 M | 298 M | 298 M | 298 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 8.72 M | 8.72 M | 8.72 M | 8.72 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | -251 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency